Publication Detail
The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in PubMed. This abstract is what is used to create the fingerprint of the publication. If any grants are referenced by the publication, they will be listed here as well.
Comparison of the safety and immunogenicity of delta aroC delta aroD and delta cya delta crp Salmonella typhi strains in adult volunteers.
C O Tacket; D M Hone; R Curtiss; S M Kelly; G Losonsky; L Guers; A M Harris; R Edelman; M M Levine (Profiled Author: Myron M Levine)
Department of Medicine, University of Maryland School of Medicine, Baltimore 21201.
Infection and immunity 1992;60(2):536-41.
Three attenuated Salmonella typhi strains have been constructed by introducing deletions in aroC and aroD or deletions in cya and crp into one of two wild-type parent strains, Ty2 or ISP1820. These mutant strains were designated CVD 906 (ISP1820 delta aroC delta aroD), CVD 908 (Ty2 delta aroC delta aroD), and chi 3927 (Ty2 delta cya delta crp). Two studies were conducted with 36 healthy adult inpatient volunteers to determine in a double-blind fashion the safety and immunogenicity of approximately 5 x 10(4) and 5 x 10(5) CFU of each of these three vaccine candidates given as a single dose. No statistically significant difference in the incidence of reactions among vaccinees was observed. Fever (oral temperature greater than or equal to 38.2 degrees C) occurred in 2 of 12 volunteers who received CVD 906, in 0 of 12 who received CVD 908, and in 1 of 12 who received chi 3927. Vaccine bacteremia without symptoms occurred in 1 of 12 vaccinees who received CVD 906, in 0 of 12 who received CVD 908, and in 2 of 12 who received chi 3927. Overall, 19 (53%) of 36 vaccinees developed immunoglobulin G antibody to S. typhi lipopolysaccharide after vaccination, with no statistically significant differences in the rate of seroconversion among volunteers in the three groups. We conclude that defined mutations in the aromatic biosynthetic pathway and in the cyclic AMP global regulatory system attenuate S. typhi. Mutant strains CVD 906, CVD 908, and chi 3927 are highly (and approximately equally) immunogenic but possibly differ in their propensity to induce fever. Further studies are needed to document the apparent relative safety of CVD 908 as a typhoid vaccine and as a vaccine carrier of foreign antigens.
13 Originating Grant
-
1.
Levine, Myron Max
Recombinant & live oral Salmonella typhi hybrid vaccines
1 April 1990 - 28 February 2009
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
-
2.
LEVINE, MYRON M
-
3.
LEVINE, MYRON M
-
4.
LEVINE, MYRON M
-
5.
LEVINE, MYRON M
-
6.
LEVINE, MYRON M
-
7.
LEVINE, MYRON M
-
8.
LEVINE, MYRON M
-
9.
LEVINE, MYRON M
-
10.
LEVINE, MYRON M
-
11.
LEVINE, MYRON M
-
12.
LEVINE, MYRON M
-
13.
LEVINE, MYRON M
Scientific Context
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts and related grants with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Related Publications
-
1.
1992C O Tacket; D M Hone; G A Losonsky; L Guers; R Edelman; M M Levine
Clinical acceptability and immunogenicity of CVD 908 Salmonella typhi vaccine strain.
Vaccine 1992;10(7):443-6. -
2.
1995S J Cryz; J U Que; M M Levine; G Wiedermann; H Kollaritsch
Infection and immunity 1995;63(4):1336-9. -
3.
2012Rezwanul Wahid; Raphael Simon; Shah J Zafar; Myron M Levine; Marcelo B Sztein
Clinical and vaccine immunology : CVI 2012;19(6):825-34.

Appears in this Publication








